{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T09:50:30Z","timestamp":1726221030609},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,1,14]],"date-time":"2011-01-14T00:00:00Z","timestamp":1294963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s10072-010-0469-0","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T13:02:12Z","timestamp":1294923732000},"page":"351-358","source":"Crossref","is-referenced-by-count":14,"title":["Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group\u2014Italian Neurological Society"],"prefix":"10.1007","volume":"32","author":[{"name":"MS-SIN Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ghezzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. M. E.","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. G.","family":"Marrosu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Comi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bertolotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Trojano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Capra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Millefiorini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sotgiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Brescia Morra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. P.","family":"Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lugaresi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Mancardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Montanari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Provinciali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Durelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bellantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. R.","family":"Tola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Cottone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Savettieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,14]]},"reference":[{"key":"469_CR1","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1212\/01.WNL.0000158329.30470.D0","volume":"64","author":"GP Rice","year":"2005","unstructured":"Rice GP, Hartung HP, Calabresi PA (2005) Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64:1336\u20131342","journal-title":"Neurology"},{"key":"469_CR2","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1468-1331.2009.02532.x","volume":"16","author":"M Khademi","year":"2009","unstructured":"Khademi M, Bornsen L, Rafatnia F et al (2009) The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 16:528\u2013536","journal-title":"Eur J Neurol"},{"key":"469_CR3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899\u2013910","journal-title":"N Engl J Med"},{"key":"469_CR4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911\u2013923","journal-title":"N Engl J Med"},{"key":"469_CR5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW, Green AJ et al (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375\u2013381","journal-title":"N Engl J Med"},{"key":"469_CR6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","volume":"353","author":"BK Kleinschmidt-DeMasters","year":"2005","unstructured":"Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353:369\u2013374","journal-title":"N Engl J Med"},{"key":"469_CR7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Assche Van","year":"2005","unstructured":"Van Assche G, Van Ranst M, Sciot R et al (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease. N Engl J Med 353:362\u2013368","journal-title":"N Engl J Med"},{"key":"469_CR8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","volume":"354","author":"TA Yousry","year":"2006","unstructured":"Yousry TA, Major EO, Ryschkewitsch C et al (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924\u2013933","journal-title":"N Engl J Med"},{"key":"469_CR9","unstructured":"Commissione delle Comunit\u00e0 Europee, decisione della commisione del 27-VI-2006 che accorda a norma del regolamento (CE) n. 726\/2004 del Parlamento europeo e del Consiglio l\u2019autorizzazione ad immettere in commercio il \u201cTysabri-natalizumab\u201d, un medicinale per uso umano"},{"key":"469_CR10","unstructured":"Food and Drug Administration News Release (2010) http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2006\/ucm108662.htm . Accessed 29 Sept 2010"},{"key":"469_CR11","unstructured":"Agenzia Italiana del Farmaco, determinazione del 7 dicembre (2006) http:\/\/aifa-neuro.agenziafarmaco.it\/tysabri.pdf . Accessed 29 Sept 2010"},{"key":"469_CR12","unstructured":"Mancardi GL, Tedeschi G, Amato MP et al (2010) Three years of experience: the Italian registry and safety data update. Neurol Sci. 20 July 2010 [Epub ahead of print]"},{"key":"469_CR13","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","volume":"9","author":"DB Clifford","year":"2010","unstructured":"Clifford DB, De Luca A, Simpson DM et al (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9:438\u2013446","journal-title":"Lancet Neurol"},{"key":"469_CR14","unstructured":"Biogen Idec (2010) http:\/\/www.biogenidec.ch\/ . Accessed 29 Sept 2010"},{"key":"469_CR15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000276400","volume":"63","author":"N Putzki","year":"2010","unstructured":"Putzki N, Yaldizli O, B\u00fchler R et al (2010) Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol 63:101\u2013106","journal-title":"Eur Neurol"},{"key":"469_CR16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00415-009-5294-0","volume":"257","author":"O Outteryck","year":"2010","unstructured":"Outteryck O, Ongagna JC, Z\u00e9phir H et al (2010) Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol 257:207\u2013211","journal-title":"J Neurol"},{"key":"469_CR17","doi-asserted-by":"crossref","unstructured":"Belachew S, Phan-Ba R, Bartholom\u00e9 E et al (2010) Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol. doi: 10.1111\/j.1468-1331.2010.03112.x","DOI":"10.1111\/j.1468-1331.2010.03112.x"},{"key":"469_CR18","doi-asserted-by":"crossref","unstructured":"Piehl F, Holm\u00e9n C, Hillert J et al (2010) Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurol Sci. doi: 10.1007\/s10072-010-0345-y","DOI":"10.1007\/s10072-010-0345-y"},{"key":"469_CR19","doi-asserted-by":"crossref","unstructured":"Sangalli F, Moiola L, Bucello S et al (2010) Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci. doi: 10.1007\/s10072-010-0344-z","DOI":"10.1007\/s10072-010-0344-z"},{"key":"469_CR20","doi-asserted-by":"crossref","unstructured":"Prosperini L, Borriello G, Fubelli F et al (2010) Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. Neurol Sci. doi: 10.1007\/s10072-010-0348-8","DOI":"10.1007\/s10072-010-0348-8"},{"key":"469_CR21","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1212\/WNL.41.7.980","volume":"41","author":"DS Goodin","year":"1991","unstructured":"Goodin DS (1991) The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical review. Neurology 41:980\u2013985","journal-title":"Neurology"},{"key":"469_CR22","unstructured":"Martinelli V, Bergamaschi R, Bellantonio P et al (2010) Incidence of acute myeloid leukemia and related mortality in Italian MS patients treated with mitoxantrone. Mult Scler (Suppl 10): P480"},{"key":"469_CR23","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1212\/WNL.0b013e3181dc1ae0","volume":"74","author":"JJ Marriott","year":"2010","unstructured":"Marriott JJ, Miyasaki JM, Gronseth G et al (2010) Evidence Report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the therapeutics and technology Assessment subcommittee of the American Academy of Neurology. Neurology 74:1463\u20131470","journal-title":"Neurology"},{"key":"469_CR24","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1212\/WNL.0b013e3181f11daf","volume":"75","author":"A Ghezzi","year":"2010","unstructured":"Ghezzi A, Pozzilli C, Grimaldi LM et al (2010) Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology 75:912\u2013917","journal-title":"Neurology"},{"key":"469_CR25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","volume":"68","author":"L Gorelik","year":"2010","unstructured":"Gorelik L, Lerner M, Bixler S et al (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68:295\u2013303","journal-title":"Ann Neurol"},{"key":"469_CR26","unstructured":"Cristiano LM, Bozic C, Kooijmans M (2010) Preliminary evaluation of pregnancy outcomes from the TYSABRI (natalizumab) pregnancy exposure registry.In: Poster P01.185 presented at the 62nd annual meeting of the American Academy of Neurology, Toronto"},{"key":"469_CR27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1474-4422(07)70078-9","volume":"6","author":"L Kappos","year":"2007","unstructured":"Kappos L, Bates D, Hartung HP et al (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6:431\u2013441","journal-title":"Lancet Neurol"},{"key":"469_CR28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","volume":"72","author":"BO Khatri","year":"2009","unstructured":"Khatri BO, Man S, Giovannoni G et al (2009) Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72:402\u2013409","journal-title":"Neurology"},{"key":"469_CR29","doi-asserted-by":"crossref","unstructured":"Schr\u00f6der A, Lee DH, Hellwig K et al (2010) successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol. doi: 10.1001\/archneurol.2010.157","DOI":"10.1001\/archneurol.2010.157"},{"key":"469_CR30","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMoa0810257","volume":"361","author":"W Wenning","year":"2009","unstructured":"Wenning W, Haghikia A, Laubenberger J et al (2009) Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 361:1075\u20131080","journal-title":"N Engl J Med"},{"key":"469_CR31","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11910-010-0138-y","volume":"10","author":"M McCarthy","year":"2010","unstructured":"McCarthy M, Nath A (2010) Neurologic consequences of the immune reconstitution inflammatory syndrome (IRIS). Curr Neurol Neurosci Rep 10:467\u2013475","journal-title":"Curr Neurol Neurosci Rep"},{"key":"469_CR32","unstructured":"Grimaldi LME et al (2010) An MRI study of the therapeutic window in natalizumab treated MS patients (submitted)"},{"issue":"13 Pt 2","key":"469_CR33","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","volume":"70","author":"MM Vellinga","year":"2008","unstructured":"Vellinga MM, Castelijns JA, Barkhof F et al (2008) Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70(13 Pt 2):1150\u20131151","journal-title":"Neurology"},{"key":"469_CR34","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1212\/01.wnl.0000327341.89587.76","volume":"72","author":"O St\u00fcve","year":"2009","unstructured":"St\u00fcve O, Cravens PD, Frohman EM et al (2009) Immunologic, clinical, and radiologic status 14\u00a0months after cessation of natalizumab therapy. Neurology 72:396\u2013401","journal-title":"Neurology"},{"key":"469_CR35","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/ana.22074","volume":"68","author":"J Killestein","year":"2010","unstructured":"Killestein J, Vennegoor A, Strijbis EM et al (2010) Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 68:392\u2013395","journal-title":"Ann Neurol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-010-0469-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-010-0469-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-010-0469-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T16:36:32Z","timestamp":1559925392000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-010-0469-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,14]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["469"],"URL":"https:\/\/doi.org\/10.1007\/s10072-010-0469-0","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2011,1,14]]}}}